Oncologic emergencies

Critical Care Medicine

Volumn 40, Issue 7, 2012, Pages 2212-2222

  McCurdy, Michael T ^a,b   Shanholtz, Carl B ^a  

^a Division of Pulmonary and Critical Care Medicine   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adult; hypercalcemia; malignancy; spinal cord compression; superior vena cava syndrome; tumor lysis syndrome

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; DEXAMETHASONE; GADOLINIUM; GALLIUM NITRATE; GLUCOCORTICOID; GLUCONATE CALCIUM; INSULIN; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; PAMIDRONIC ACID; PHOSPHATE BINDING AGENT; POLYSTYRENESULFONIC ACID; RASBURICASE; RITUXIMAB; STEROID; TAMOXIFEN; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; DIAGNOSTIC PROCEDURE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EMERGENCY CARE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANCY ASSOCIATED HYPERCALCEMIA; MALIGNANT SPINAL CORD COMPRESSION; MEDICAL LITERATURE; NEPHROTOXICITY; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; SOLID TUMOR; SPINAL CORD COMPRESSION; SUPERIOR CAVA VEIN SYNDROME; THROMBOSIS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

ADRENAL CORTEX HORMONES; BACK PAIN; CARDIAC TAMPONADE; CRITICAL ILLNESS; DIAGNOSTIC IMAGING; DYSPNEA; EDEMA; EMERGENCIES; HUMANS; HYPERCALCEMIA; INTENSIVE CARE; NEOPLASMS; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; SPINAL CORD COMPRESSION; SUPERIOR VENA CAVA SYNDROME; TUMOR LYSIS SYNDROME;

EID: 84862756818     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31824e1865     Document Type: Review

References (144)

1. Xu J, Kochanek KD, Murphy SL, et al: Deaths: Final data for 2007. National Vital Statistics Reports; Vol 58 No 19. Hyattsville, MD, National Center for Health Statistics, 2010
2. Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2005. Bethesda, MD, National Cancer Institute, 2008
3. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103:117-128
4. Schiff D, O'Neill BP, Suman VJ: Spinal epidural metastasis as the initial manifestation of malignancy: Clinical features and diagnostic approach. Neurology 1997; 49:452-456 (Pubitemid 27368881)
5. Pizzo PA: Fever in immunocompromised patients. N Engl J Med 1999; 341:893-900 (Pubitemid 29427053)
6. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751 (Pubitemid 34194843)
7. Stehbens WE: History of aneurysms. Med Hist 1958; 2:274-280
8. McCurdy MT, Mitarai T, Perkins J: Oncologic emergencies, part I: Spinal cord compression, superior vena cava syndrome, and pericardial effusion. Emerg Med Pract 2010; 12:1-20
9. Wilson LD, Detterbeck FC, Yahalom J: Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356:1862-1869 (Pubitemid 46698467)
10. Armstrong BA, Perez CA, Simpson JR, et al: Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987; 13:531-539 (Pubitemid 17069648)
11. Rice TW, Rodriguez RM, Light RW: The superior vena cava syndrome: Clinical characteristics and evolving etiology. Medicine (Baltimore) 2006; 85:37-42 (Pubitemid 43884285)
12. Urschel HC Jr, Razzuk MA, Netto GJ, et al: Sclerosing mediastinitis: Improved management with histoplasmosis titer and ketoconazole. Ann Thorac Surg 1990; 50: 215-221 (Pubitemid 20255942)
13. Mineo TC, Ambrogi V, Nofroni I, et al: Mediastinoscopy in superior vena cava obstruction: Analysis of 80 consecutive patients. Ann Thorac Surg 1999; 68:223-226 (Pubitemid 29338994)
14. Jahangiri M, Goldstraw P: The role of mediastinoscopy in superior vena caval obstruction. Ann Thorac Surg 1995; 59:453-455
15. Kim HC, Chung JW, Park SH, et al: Systemic-to-pulmonary venous shunt in superior vena cava obstruction: Depiction on computed tomography venography. Acta Radiol 2004; 45:269-274
16. Yellin A, Rosen A, Reichert N, et al: Superior vena cava syndrome. The myth-the facts. Am Rev Respir Dis 1990; 141(5 Pt 1):1114-1118 (Pubitemid 20172558)
17. Ahmann FR: A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 1984; 2:961-969 (Pubitemid 14037777)
18. Abner A: Approach to the patient who presents with superior vena cava obstruction. Chest 1993; 103(4 Suppl):394S-397S (Pubitemid 23110362)
19. Rice TW: Pleural effusions in superior vena cava syndrome: Prevalence, characteristics, and proposed pathophysiology. Curr Opin Pulm Med 2007; 13:324-327 (Pubitemid 46847299)
20. Schraufnagel DE, Hill R, Leech JA, et al: Superior vena caval obstruction. Is it a medical emergency? Am J Med 1981; 70:1169-1174 (Pubitemid 11072108)
21. Chan RH, Dar AR, Yu E, et al: Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys 1997; 38:513-520 (Pubitemid 27305011)
22. Yellin A, Mandel M, Rechavi G, et al: Superior vena cava syndrome associated with lymphoma. Am J Dis Child 1992; 146:1060-1063
23. Yu JB, Wilson LD, Detterbeck FC: Superior vena cava syndrome- A proposed classification system and algorithm for management. J Thorac Oncol 2008; 3:811-814
24. Marcy PY, Magné N, Bentolila F, et al: Superior vena cava obstruction: Is stenting necessary? Support Care Cancer 2001; 9:103-107 (Pubitemid 32246456)
25. Wilkes JD, Fidias P, Vaickus L, et al: Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer 1995; 76:1377-1387
26. Tsang TS, Oh JK, Seward JB: Diagnosis and management of cardiac tamponade in the era of echocardiography. Clin Cardiol 1999; 22:446-452 (Pubitemid 29302753)
27. Imazio M, Demichelis B, Parrini I, et al: Relation of acute pericardial disease to malignancy. Am J Cardiol 2005; 95:1393-1394 (Pubitemid 40719880)
28. Karam N, Patel P, deFilippi C: Diagnosis and management of chronic pericardial effusions. Am J Med Sci 2001; 322:79-87
29. Spodick DH: Acute cardiac tamponade. N Engl J Med 2003; 349:684-690 (Pubitemid 36976001)
30. Wagner PL, McAleer E, Stillwell E, et al: Pericardial effusions in the cancer population: Prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability. J Thorac Cardiovasc Surg 2011; 141:34-38
31. Barron KD, Hirano A, Araki S, et al: Experiences with metastatic neoplasms involving the spinal cord. Neurology 1959; 9:91-106
32. Bach F, Larsen BH, Rohde K, et al: Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990; 107:37-43
33. Loblaw DA, Laperriere NJ, Mackillop WJ: A population-based study of malignant spinal cord compression in Ontario. Clin Oncol (R Coll Radiol) 2003; 15:211-217 (Pubitemid 36722768)
34. Sørensen S, Børgesen SE, Rohde K, et al: Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer 1990; 65:1502-1508 (Pubitemid 20106106)
35. Schiff D, O'Neill BP: Intramedullary spinal cord metastases: Clinical features and treatment outcome. Neurology 1996; 47:906-912
36. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982; 49:759-772 (Pubitemid 12165435)
37. Schiff D: Spinal cord compression. Neurol Clin 2003; 21:67-86, viii (Pubitemid 36169345)
38. Arguello F, Baggs RB, Duerst RE, et al: Pathogenesis of vertebral metastasis and epidural spinal cord compression. Cancer 1990; 65:98-106 (Pubitemid 20026818)
39. Prasad D, Schiff D: Malignant spinal-cord compression. Lancet Oncol 2005; 6:15-24 (Pubitemid 40089716)
40. American Cancer Society: Cancer facts and figures. Atlanta, GA, American Cancer Society, 2010
41. Posner JB: Neurologic Complications of Cancer. Philadelphia, F.A. Davis, 1995
42. Rodichok LD, Harper GR, Ruckdeschel JC, et al: Early diagnosis of spinal epidural metastases. Am J Med 1981; 70:1181-1188 (Pubitemid 11072110)
43. Schiff D, Batchelor T, Wen PY: Neurologic emergencies in cancer patients. Neurol Clin 1998; 16:449-483 (Pubitemid 28225359)
44. elweg-Larsen S, Sørensen PS: Symptoms and signs in metastatic spinal cord compression: A study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer 1994; 30A:396-398 (Pubitemid 24152485)
45. Husband DJ: Malignant spinal cord compression: Prospective study of delays in referral and treatment. BMJ 1998; 317:18-21 (Pubitemid 28333819)
46. Husband DJ, Grant KA, Romaniuk CS: MRI in the diagnosis and treatment of suspected malignant spinal cord compression. Br J Radiol 2001; 74:15-23 (Pubitemid 32156626)
47. Deyo RA, Rainville J, Kent DL: What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760-765
48. Maranzano E, Latini P: Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: Final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995; 32:959-967
49. Li KC, Poon PY: Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. Magn Reson Imaging 1988; 6:547-556
50. Kim JK, Learch TJ, Colletti PM, et al: Diagnosis of vertebral metastasis, epidural metastasis, and malignant spinal cord compression: Are T(1)-weighted sagittal images sufficient? Magn Reson Imaging 2000; 18:819-824
51. Cook AM, Lau TN, Tomlinson MJ, et al: Magnetic resonance imaging of the whole spine in suspected malignant spinal cord compression: Impact on management. Clin Oncol (R Coll Radiol) 1998; 10:39-43 (Pubitemid 28112376)
52. elweg-Larsen S, Hansen SW, Sørensen PS: Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Int J Radiat Oncol Biol Phys 1995; 33:595-598
53. Van der Sande JJ, Kröger R, Boogerd W: Multiple spinal epidural metastases; an unexpectedly frequent finding. J Neurol Neurosurg Psychiatr 1990; 53:1001-1003 (Pubitemid 20378906)
54. Schiff D, O'Neill BP, Wang CH, et al: Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. Cancer 1998; 83:1593-1601 (Pubitemid 28465477)
55. Khanna AJ, Shindle MK, Wasserman BA, et al: Use of magnetic resonance imaging in differentiating compartmental location of spinal tumors. Am J Orthop 2005; 34:472-476
56. Sze G, Krol G, Zimmerman RD, et al: Intramedullary disease of the spine: Diagnosis using gadolinium-DTPA-enhanced MR imaging. AJR Am J Roentgenol 1988; 151:1193-1204
57. Hagenau C, Grosh W, Currie M, et al: Comparison of spinal magnetic resonance imaging and myelography in cancer patients. J Clin Oncol 1987; 5:1663-1669
58. elweg-Larsen S, Wagner A, Kjaer L, et al: Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. J Neurooncol 1992; 13:231-237
59. Hollis PH, Malis LI, Zappulla RA: Neurological deterioration after lumbar puncture below complete spinal subarachnoid block. J Neurosurg 1986; 64:253-256 (Pubitemid 16140339)
60. Portenoy RK, Galer BS, Salamon O, et al: Identification of epidural neoplasm. Radiography and bone scintigraphy in the symptomatic and asymptomatic spine. Cancer 1989; 64:2207-2213 (Pubitemid 19282832)
61. O'Rourke T, George CB, Redmond J 3rd, et al: Spinal computed tomography and computed tomographic metrizamide myelography in the early diagnosis of metastatic disease. J Clin Oncol 1986; 4:576-583 (Pubitemid 16117951)
62. Rades D, Blach M, Bremer M, et al: Prognostic significance of the time of developing motor deficits before radiation therapy in metastatic spinal cord compression: One-year results of a prospective trial. Int J Radiat Oncol Biol Phys 2000; 48:1403-1408
63. Yeung SCJ, Escalante CP: Oncologic emergencies. In: Holland-Frei Cancer Medicine. Seventh Edition. Kufe DW, Bast Jr. RC, Hait W, et al (Eds). Hamilton, Ontario, BC Decker, 2006, pp xxiii, p. 2328
64. Sørensen S, Helweg-Larsen S, Mouridsen H, et al: Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomised trial. Eur J Cancer 1994; 30A:22-27 (Pubitemid 24058082)
65. Heimdal K, Hirschberg H, Slettebø H, et al: High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 1992; 12:141-144
66. Loblaw DA, Perry J, Chambers A, et al: Systematic review of the diagnosis and management of malignant extradural spinal cord compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005; 23:2028-2037 (Pubitemid 46211383)
67. Young RF, Post EM, King GA: Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 1980; 53:741-748 (Pubitemid 11194432)
68. Gilbert RW, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 1978; 3:40-51
69. Sciubba DM, Petteys RJ, Dekutoski MB, et al: Diagnosis and management of metastatic spine disease. J Neurosurg Spine 2010; 13:94-108
70. Patchell RA, Tibbs PA, Regine WF, et al: Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial. Lancet 2005; 366:643-648 (Pubitemid 41176016)
71. Cole JS, Patchell RA: Metastatic epidural spinal cord compression. Lancet Neurol 2008; 7:459-466 (Pubitemid 351508481)
72. Stewart AF: Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373-379
73. Lee CT, Yang CC, Lam KK, et al: Hypercalcemia in the emergency department. Am J Med Sci 2006; 331:119-123
74. Ralston SH, Gallacher SJ, Patel U, et al: Cancer-associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990; 112:499-504 (Pubitemid 20100287)
75. McCurdy MT, Mitarai T, Perkins J: Oncologic emergencies, part II: Neutropenic fever, tumor lysis syndrome, and hypercalcemia of malignancy. Emerg Med Pract 2010; 12:1-24
76. Ratcliffe WA, Hutchesson AC, Bundred NJ, et al: Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339: 164-167
77. Seymour JF, Gagel RF: Calcitriol: The major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82: 1383-1394 (Pubitemid 23263952)
78. Bilezikian JP: Clinical review 51: Management of hypercalcemia. J Clin Endocrinol Metab 1993; 77:1445-1449 (Pubitemid 24000893)
79. National Cancer Institute: PDQ® Hypercalcemia. Available at: http://cancer. gov/cancertopics/pdq/supportivecare/hypercalcemia/ healthprofessional. Accessed December 29, 2010
80. Ladenson JH, Lewis JW, Boyd JC: Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab 1978; 46: 986-993 (Pubitemid 8358365)
81. Ijaz A, Mehmood T, Qureshi AH, et al: Estimation of ionized calcium, total calcium and albumin corrected calcium for the diagnosis of hypercalcaemia of malignancy. J Coll Physicians Surg Pak 2006; 16:49-52
82. Slomp J, Van der Voort PH, Gerritsen RT, et al: Albumin-adjusted calcium is not suitable for diagnosis of hyper-and hypocalcemia in the critically ill. Crit Care Med 2003; 31:1389-1393 (Pubitemid 36583848)
83. Wang S, McDonnell EH, Sedor FA, et al: pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med 2002; 126:947-950
84. Milionis HJ, Rizos E, Liamis G, et al: Acid-base and electrolyte disturbances in patients with hypercalcemia. South Med J 2002; 95:1280-1287 (Pubitemid 36109337)
85. Farr HW, Fahey TJ Jr, Nash AG, et al: Primary hyperparathyroidism and cancer. Am J Surg 1973; 126:539-543
86. Fritchie K, Zedek D, Grenache DG: The clinical utility of parathyroid hormone-related peptide in the assessment of hypercalcemia. Clin Chim Acta 2009; 402:146-149
87. Wimalawansa SJ: Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73:2223-2230 (Pubitemid 24107981)
88. Rizzoli R, Thiébaud D, Bundred N, et al: Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999; 84: 3545-3550 (Pubitemid 30645203)
89. Behl D, Hendrickson AW, Moynihan TJ: Oncologic emergencies. Crit Care Clin 2010; 26:181-205
90. Antzelevitch C, Brugada P, Borggrefe M, et al: Brugada syndrome: Report of the second consensus conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659-670
91. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1-203
92. Kvols LK: Neoplasms of the diffuse endocrine system. In: Cancer Medicine. Sixth Edition. Holland JF, Frei III E (Eds). Hamilton, Ontario, BC Decker, 2003, pp 1275-1323
93. Hosking DJ, Cowley A, Bucknall CA: Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981; 50:473-481 (Pubitemid 12162746)
94. Nkwuo N, Schamban N, Borenstein M: Selected oncologic emergencies. In: Rosen's Emergency Medicine: Concepts and Clinical Practice. Sixth Edition. Marx JA, Hockberger RS, Walls RM (Eds). Philadelphia, PA, Mosby, 2006, pp 1914-1916
95. Body JJ: Hypercalcemia of malignancy. Semin Nephrol 2004; 24:48-54
96. Koo WS, Jeon DS, Ahn SJ, et al: Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996; 72:424-428 (Pubitemid 26059574)
97. Davies M, Hayes ME, Yin JA, et al: Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 1994; 78:1202-1207 (Pubitemid 24143047)
98. Mudde AH, Van den Berg H, Boshuis PG, et al: Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer 1987; 59:1543-1546 (Pubitemid 17060092)
99. Chisholm MA, Mulloy AL, Taylor AT: Acute management of cancer-related hypercalcemia. Ann Pharmacother 1996; 30:507-513 (Pubitemid 26139248)
100. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112:352-364 (Pubitemid 20083611)
101. Strumpf M, Kowalski MA, Mundy GR: Effects of glucocorticoids on osteoclast-activating factor. J Lab Clin Med 1978; 92:772-778 (Pubitemid 9058665)
102. Fleisch H: Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42:919-944 (Pubitemid 21920790)
103. Layman R, Olson K, Van Poznak C: Bisphosphonates for breast cancer: Questions answered, questions remaining. Hematol Oncol Clin North Am 2007; 21:341-367 (Pubitemid 46754735)
104. Woo SB, Hellstein JW, Kalmar JR: Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761 (Pubitemid 46780635)
105. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-567 (Pubitemid 32112871)
106. Silva OL, Becker KL: Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 1973; 132:337-339
107. Chitambar CR: Apoptotic mechanisms of gallium nitrate: Basic and clinical investigations. Oncology (Williston Park, NY) 2004; 18(13 Suppl 10):39-44
108. Cvitkovic F, Armand JP, Tubiana-Hulin M, et al: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 2006; 12:47-53
109. Thürlimann B, Waldburger R, Senn HJ, et al: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial. Ann Oncol 1992; 3:619-623
110. Fizazi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564-1571
111. Henry DH, von Moos R, Hungria V: Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. J Clin Oncol 2010; 28:A9133
112. Lipton A, Stopeck A, Von Moos R: A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid for treatment of bone metastases. J Clin Oncol 2010; 28:A9015
113. Cairo MS, Coiffier B, Reiter A, et al; TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol 2010; 149:578-586
114. Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med 2011; 364:1844-1854
115. Davidson MB, Thakkar S, Hix JK, et al: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116:546-554 (Pubitemid 38452647)
116. Cairo MS, Bishop M: Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol 2004; 127:3-11 (Pubitemid 39331101)
117. Lameire NH, Flombaum CD, Moreau D, et al: Acute renal failure in cancer patients. Ann Med 2005; 37:13-25 (Pubitemid 40342421)
118. Baeksgaard L, Sørensen JB: Acute tumor lysis syndrome in solid tumors- A case report and review of the literature. Cancer Chemother Pharmacol 2003; 51:187-192 (Pubitemid 36469946)
119. Cohen LF, Balow JE, Magrath IT, et al: Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68:486-491 (Pubitemid 10141811)
120. Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133-139 (Pubitemid 23046437)
121. Coiffier B, Mounier N, Bologna S, et al; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21:4402-4406
122. Bosly A, Sonet A, Pinkerton CR, et al: Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study. Cancer 2003; 98:1048-1054 (Pubitemid 37022107)
123. Hsu HH, Huang CC: Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol 2004; 79:48-51
124. Coiffier B, Altman A, Pui CH, et al: Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008; 26:2767-2778
125. Koduri PR: Hyperphosphatemia and tumor lysis syndrome. Ann Hematol 2005; 84:696
126. Desmeules S, Bergeron MJ, Isenring P: Acute phosphate nephropathy and renal failure. N Engl J Med 2003; 349:1006-1007 (Pubitemid 37064780)
127. Darmon M, Guichard I, Vincent F, et al: Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 2010; 51:221-227
128. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, et al: Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31:27-28 (Pubitemid 28243698)
129. Pui CH, Jeha S, Irwin D, et al: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: Results of a compassionate-use trial. Leukemia 2001; 15:1505-1509 (Pubitemid 32994667)
130. Pui CH, Mahmoud HH, Wiley JM, et al: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19:697-704 (Pubitemid 32119083)
131. Pui CH: Rasburicase: A potent uricolytic agent. Expert Opin Pharmacother 2002; 3:433-442
132. Jeha S, Kantarjian H, Irwin D, et al: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial. Leukemia 2005; 19:34-38 (Pubitemid 40090073)
133. Goldman SC, Holcenberg JS, Finklestein JZ, et al: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97:2998-3003
134. Arnold TM, Reuter JP, Delman BS, et al: Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004; 38:1428-1431 (Pubitemid 39100196)
135. Trifilio S, Gordon L, Singhal S, et al: Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006; 37:997-1001
136. Reeves DJ, Bestul DJ: Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008; 28:685-690 (Pubitemid 351975371)
137. McDonnell AM, Lenz KL, Frei-Lahr DA, et al: Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006; 26:806-812 (Pubitemid 43807632)
138. Knoebel RW, Lo M, Crank CW: Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract 2011; 17:147-154
139. Hutcherson DA, Gammon DC, Bhatt MS, et al: Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26:242-247 (Pubitemid 43201871)
140. Hummel M, Reiter S, Adam K, et al: Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008; 80:331-336 (Pubitemid 351347575)
141. Lee AC, Li CH, So KT, et al: Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003; 37:1614-1617 (Pubitemid 37315101)
142. Vines AN, Shanholtz CB, Thompson JL: Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother 2010; 44:1529-1537
143. Cheuk DK, Chiang AK, Chan GC, et al: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database Syst Rev 2010; CD006945
144. Smalley RV, Guaspari A, Haase-Statz S, et al: Allopurinol: Intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000; 18:1758-1763 (Pubitemid 30220555)